About me

  • Clinical researcher and senior oncologist focused on precision dosing in oncology. Director of Research, Development, Education & Innovation (FoUUi) at Södersjukhuset; Senior Consultant in Clinical Oncology; and Adjunct Senior Lecturer at KI. I lead several academic and industry-sponsored clinical studies, and I co-supervise PhD students and postdoctoral researchers. Co-founder and board member of True Dose AB.

Research

  • - Therapeutic drug monitoring (TDM) of cytotoxic agents to individualize dosing and minimize toxicity, including capillary self-sampling and decentralized TDM. (IHI project COMFORT).

    - Precision dosing/PK-PD biomarkers; implementation into routine care. 

    - Cardio-oncology and survivorship: therapy-related cardiovascular toxicity, BRCA1/2 subgroups, and real-world outcomes. 

    - Design and conduct of clinical studies; data-driven decision support and benchmarking (H2O, 4D-PICTURE).

Teaching

  • Course director for KI PhD course “Introductory Course in Clinical Studies: From Idea to Archiving”; >300 hours planning/delivery across Medical, Biomedical and nursing specialist programs. Regular lectures on GCP, clinical studies, Precision Dosing, TDM,  cardio-oncology, and “chemo brain”; supervisor of clinical residents; trained in digital assessment (Inspera). Teaching philosophy centers on active learning and constructive feedback.

Articles

All other publications

Grants

  • Swedish Cancer Society
    1 January 2024
    Early detection of cardiovascular disease is important in order to be able to link the cause partly to different conditions but partly also to previous possible cancer treatment. The patient always thinks about his own history of treatments, symptoms or diagnoses and can put it in context. There is no in-depth survey of cardiovascular disease in cancer survivors in Sweden. The Swedish population of survivors is included in other international studies, but since cardiac care differs between different countries, we now benefit from our large Swedish quality registers and from a cardio-oncological perspective. Survival after both childhood cancer and breast cancer has increased in the last decade. However, we now see an increase in deaths due to cardiovascular disease in these two patient groups. This may be due to the presence of risk factors for cardiovascular disease. An increased understanding of the relationship between cardiovascular risk factors, cancer treatment and patient-specific factors is needed in order to better prevent cardiovascular diseases in cancer survivors. This project aims to cover this knowledge gap by using the best scientific methodology to develop models to predict cardiovascular disease and survival after a cancer diagnosis. This multi-professional cardio-oncology research group intends to verify and refine already existing risk assessment for breast cancer patients and via that knowledge develop a model for adults who have survived childhood cancer. Through modern statistics and machine learning, we develop instruments for prediction models that can eventually be used to prevent cardiovascular diseases and premature death in survivors of breast and childhood cancer. The models include a wide range of cardiovascular risk factors, treatment, patient-specific, sociodemographic and tumor biology risk factors matched with comprehensive cardiovascular quality registries

Employments

  • Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026
  • Adjunct Senior Lecturer, Department of Oncology-Pathology, Karolinska Institutet, 2023-2025

Degrees and Education

  • Docent, Karolinska Institutet, 2022
  • Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2012

News from KI

Events from KI